5d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...
CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting ...
A sales partner offered a ray of hope that this company couldn't for itself.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results